TOVXHealthcare · BiotechnologyTOVX Stock Forecast: Theriva Biologics, Inc. Price Predictions for 2026-2027
The 2 Wall Street analysts covering Theriva Biologics, Inc. hold a median 12-month price target of $2.5 — +1022.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 40 of 100 as at 1 Aug 2026 — in the lower half.
TOVX stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Theriva Biologics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (92): Smaller than most of the companies we track.
Issuance (10): The company has been issuing shares or taking on financing, diluting existing holders.
The rank is the raw material. Whether the rules would actually own Theriva Biologics, Inc. — and when they’d sell — is the membership.
TOVX stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on TOVX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +1022.6% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 31 Mar 2026 | Maxim Group | Upgrade | Buy | — |
| 8 May 2025 | Maxim Group | Downgrade | Hold | — |
| 13 Nov 2024 | Maxim Group | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
TOVX analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Theriva Biologics, Inc. (TOVX) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 0.1×
- Price / sales
- 32.7×
- Price / book
- 0.6×
- EV / EBITDA
- 0.1×
Cheaper than 72% of US stocks
Cheaper than 7% of US stocks
Cheaper than 82% of US stocks
Cheaper than 61% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- −709.0%
- Net margin
- 0.0%
Higher than 7% of US stocks
Higher than 30% of US stocks
- Return on equity
- −138.9%
- Return on assets
- −22.6%
- Dividend yield
- 2767.5%
Higher than 10% of US stocks
Higher than 18% of US stocks
Higher than 99% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
TOVX vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. TOVX appears on the weeks it earns a place.
Frequently asked questions about TOVX stock
What is the TOVX stock price forecast for 2026-2027?
The 2 Wall Street analysts covering Theriva Biologics, Inc. have a median 12-month price target of $2.5, with estimates ranging from $1 to $4. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is TOVX stock a buy right now?
Of the 2 analysts covering Theriva Biologics, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Theriva Biologics, Inc. 40 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank TOVX?
As at 1 Aug 2026, Theriva Biologics, Inc. ranks 40 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (92 of 100).
Will TOVX stock go up?
No one can know that. What the data says: the median 12-month target from 2 analysts implies +1022.6% from the last close, and Ticker Nerd's factor model ranks Theriva Biologics, Inc. 40 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the TOVX stock forecast for 2030?
No analyst covering Theriva Biologics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TOVX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1 to $4 over the next 12 months.
How has TOVX stock performed over the past year?
Theriva Biologics, Inc. returned -48.2% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Theriva Biologics, Inc. do?
Theriva Biologics, Inc. is a clinical-stage immuno-oncology company specializing in the development of oncolytic virus therapeutics aimed at treating cancer and related diseases with high unmet medical needs.
About Theriva Biologics, Inc.
Theriva Biologics, Inc. is a clinical-stage immuno-oncology company specializing in the development of oncolytic virus therapeutics aimed at treating cancer and related diseases with high unmet medical needs. Its innovative approach involves engineered oncolytic adenoviruses designed to selectively replicate within and destroy tumor cells while overcoming the physical and immunosuppressive barriers that hinder current cancer treatments. The company’s lead candidates include VCN-01, an oncolytic virus targeting solid tumors to promote tumor cell death and enhance immune response; SYN-004, aimed at preventing gastrointestinal damage from antibiotics; and SYN-020, an oral enzyme formulation addressing gastrointestinal and systemic conditions. Theriva’s therapies have potential applications across a broad range of difficult-to-treat cancers and may be combined with existing cancer therapies to improve patient outcomes. Established as a diversified clinical-stage biotechnology firm, Theriva Biologics plays a significant role in advancing novel immuno-oncology solutions within the biotechnology and pharmaceutical sectors.
CEO Mr. Steven A. Shallcross CPA · 15 employees · United States · https://therivabio.com